Peter Schmid, MD, PhD, on a Possible Practice-Changing Regimen for Patients With Early-Stage, High-Risk TNBC

Posted: Thursday, February 10, 2022

Peter Schmid, MD, PhD, of Barts Cancer Institute, talks about whether the phase III findings of KEYNOTE-522, which showed a benefit to combining pembrolizumab with chemotherapy for patients with early-stage, high-risk triple-negative breast cancer, could become a practice-changing regimen.